Article

Gene editing of BTK using CRISPR/Cas9 to study drug resistance in acute myeloid leukaemia

2019-01-01

Abstract excerpt

Acute myeloid leukaemia (AML) has a current poor 5-year survival rate of only 27%, making the finding of new therapeutic avenues for treatment crucial. Bruton's tyrosine kinase (BTK) is best known for its role in B-cell receptor signalling but is found to be expressed and constitutively phosphorylated in AML cell lines and patient-derived cells. Targeting BTK in B-cell malignancies with small molecule BTK inhibito...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8bb7b161-cb51-549a-ac8f-3d2e9aacf410
DOI: 10.17638/03046051

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Gene editing of BTK using CRISPR/Cas9 to study drug resistance in acute myeloid leukaemiaDOI 10.17638/03046051Read

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.Semantic proximity Read

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.Semantic proximity Read

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathwaysSemantic proximity Read

Role of Bruton’s tyrosine kinase in B cells and malignanciesSemantic proximity Read

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read

Evaluating ibrutinib, pirtobrutinib, remibrutinib, rilzabrutinib, and zanubrutinib in 34 BTK-variants at 7 inhibitor resistance sitesSemantic proximity Read

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read